Raelipskie Partnership’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.23M Sell
12,722
-31
-0.2% -$7.22K 1.22% 18
2026
Q1
$3.12M Sell
12,753
-529
-4% -$123K 1.32% 17
2025
Q4
$2.75M Sell
13,282
-360
-3% -$71.2K 1.15% 20
2025
Q3
$2.53M Buy
13,642
+5
+0% +$857 1.09% 23
2025
Q2
$2.08M Buy
13,637
+100
+0.7% +$15.4K 0.95% 26
2025
Q1
$2.24M Buy
13,537
+360
+3% +$56.3K 1.15% 20
2024
Q4
$1.91M Sell
13,177
-251
-2% -$38.9K 0.95% 26
2024
Q3
$2.18M Sell
13,428
-262
-2% -$41.7K 1.06% 21
2024
Q2
$2M Sell
13,690
-400
-3% -$59.5K 1.07% 21
2024
Q1
$2.23M Buy
14,090
+531
+4% +$84.5K 1.27% 18
2023
Q4
$2.13M Buy
+13,559
New +$2.08M 1.29% 16

Other funds holding JNJ

Raelipskie Partnership's JNJ Position: Q2 2026 in Review

Raelipskie Partnership reduced its Johnson & Johnson (JNJ) stake by 0.24% in Q2 2026, selling an estimated $7.22K and leaving 12,722 shares worth $3.23M. The position accounts for 1.22% of the portfolio, ranked #18.

Raelipskie Partnership first reported a position in JNJ in Q4 2023 and has held it in 11 quarters since. 4,688 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Raelipskie Partnership held 12,722 shares of Johnson & Johnson worth $3.23M as of Q2 2026.
  • Raelipskie Partnership sold 31 Johnson & Johnson shares in Q2 2026, an estimated $7.22K.
  • Johnson & Johnson made up 1.22% of Raelipskie Partnership's portfolio in Q2 2026, its #18 holding.
  • Raelipskie Partnership first reported a position in Johnson & Johnson in Q4 2023 and has held it in 11 quarters since.
  • 4,688 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Raelipskie Partnership's 13F filing for Q2 2026, filed 4 Aug 2026.